Nevertheless, the existence of exclusively heterozygous IDH2 (and IDH1) mutations in gliomas and AML and the small possibility of dominant-negative mutations (minor mutant fractions existing could not exert this role [39]) have led to the search for other consequences of IDH1 and IDH2 mutations. Here, IDH1 is linked to central nervous system cancer.